Oct262023

Effective Primary Care Management of Type 2 Diabetes for Indigenous Populations: A Systematic Review

Recent Publications

Indigenous peoples in high income countries are disproportionately affected by Type 2 Diabetes. Socioeconomic disadvantages and inadequate access to appropriate healthcare are important contributors. This systematic review, co-authored by Associate Professor Roy Rasalam (Principal Investigator at AusTrials Sunshine in Melbourne), investigates effective designs of primary care management of Type 2 Diabetes for Indigenous adults in…

Read article
Oct262023

GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective

Recent Publications

The ever-increasing number of drugs available to treat type 2 diabetes and the complexity of patients with this condition present a constant challenge when it comes to identifying the most appropriate treatment approach. The more recent glucagon-like peptide-1 receptor agonists (GLP-1RAs) are non-insulin injectable options for the management of type 2 diabetes. Effective at improving…

Read article
Oct262023

Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin

Recent Publications

Tirzepatide is a first-in-class GIP/GLP-1 receptor agonist (‘twincretin’)—a single molecule that acts as an agonist at both glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. In the SURPASS clinical trial program in type 2 diabetes mellitus (T2D), tirzepatide was associated with unprecedented reductions in HbA1c, clinically significant weight loss and other metabolic benefits,…

Read article
Oct262023

Early Type 2 Diabetes Treatment Intensification with Glucagon-Like Peptide-1 Receptor Agonists in Primary Care: An Australian Perspective on Guidelines and the Global Evidence

Recent Publications

Early and intensive management of type 2 diabetes has been shown to delay disease progression, reduce the risk of cardiorenal complications and prolong time to treatment failure. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are being increasingly recognized for their potential in early disease management, with recent guideline updates recommending second-line use of this injectable drug class…

Read article